Merck Serono, Cetuximab increases survival in metastatic tumors.

Merck Serono, a division of Merck KGaA (Darmstadt, Germany), announced today that Cetuximab has been shown to significantly enhance overall survival (OS) when added to standard treatment for first-line chemotherapy in patients with metastatic colorectal cancer (mCRC) with non-mutated KRAS. It said in a statement. Read More

show submisison details

What is CouponZi?

CouponZi is a Web 2.0 aggregator of hot deals, coupons, coupon codes, rebates, and special offers for the Web's top merchants. We even share our Adsense revenue when you contribute!
Subscribe To RSS

Merchant Offers

Popular Tags

Latest Comments

Popular Deals

Top Today